

Mehdi Hamadani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/178121/publications.pdf>

Version: 2024-02-01

395
papers

11,308
citations

34016

52
h-index

51492

86
g-index

401
all docs

401
docs citations

401
times ranked

9844
citing authors

#	ARTICLE	IF	CITATIONS
1	Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. <i>Blood</i> , 2022, 139, 1330-1339.	0.6	52
2	Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. <i>Blood Advances</i> , 2022, 6, 486-494.	2.5	25
3	Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies. <i>British Journal of Haematology</i> , 2022, 197, 28-40.	1.2	9
4	Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD. <i>Bone Marrow Transplantation</i> , 2022, 57, 302-303.	1.3	1
5	Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. <i>Hematological Oncology</i> , 2022, 40, 49-57.	0.8	2
6	The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e335-e339.	0.2	19
7	New indications and platforms for CAR-T therapy in lymphomas beyond DLBCL. <i>EJHaem</i> , 2022, 3, 11-23.	0.4	2
8	Characteristics and Clinical Outcomes of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Who Received At Least 3 Lines of Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 373-381.	0.2	4
9	Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. <i>Blood Advances</i> , 2022, 6, 920-930.	2.5	16
10	Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e495-e497.	0.2	2
11	Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant. <i>British Journal of Haematology</i> , 2022, 197, 212-222.	1.2	6
12	Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit. <i>Haematologica</i> , 2022, 107, 1214-1217.	1.7	5
13	Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210875.	1.1	9
14	Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T-Cell, and BiTE recipients. <i>Cancer Cell</i> , 2022, 40, 340-342.	7.7	35
15	HSR22-171: Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Older Versus Younger Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Phase 2 Clinical Trial (LOTIS-2). <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, HSR22-171.	2.3	0
16	Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome. <i>JAMA Oncology</i> , 2022, 8, 773.	3.4	11
17	Reality check: Real-world evidence to support therapeutic development in hematologic malignancies. <i>Blood Reviews</i> , 2022, 53, 100913.	2.8	7
18	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 284-293.	0.6	11

#	ARTICLE	IF	CITATIONS
19	Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e738-e744.	0.2	3
20	Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 409.e1-409.e10.	0.6	26
21	Worldwide Network for Blood and Marrow Transplantation Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 455-462.	0.6	2
22	Rap1A, Rap1B, and β -Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol. <i>Yale Journal of Biology and Medicine</i> , 2022, 95, 45-56.	0.2	0
23	THE ANTIBODY-DRUG CONJUGATE LONCASTUXIMAB TESIRINE FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA. <i>Blood</i> , 2022, , .	0.6	7
24	ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 523-529.	0.6	7
25	A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta ($\gamma\delta$) T cells in adults with B-cell malignancies. <i>Journal of Clinical Oncology</i> , 2022, 40, 7509-7509.	0.8	13
26	Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers. <i>Journal of Clinical Oncology</i> , 2022, 40, 3084-3084.	0.8	0
27	Long-term survival projections of loncastuximab tesirine-treated patients in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). <i>Journal of Clinical Oncology</i> , 2022, 40, e19551-e19551.	0.8	0
28	Phase 3 randomized study of loncastuximab tesirine in combination with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL (LOTIS-5). <i>Journal of Clinical Oncology</i> , 2022, 40, TPS7591-TPS7591.	0.8	2
29	Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis from the phase 2 PILOT study. <i>Journal of Clinical Oncology</i> , 2022, 40, 7062-7062.	0.8	4
30	Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 546-559.	0.6	16
31	Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. <i>Blood Advances</i> , 2022, 6, 4736-4739.	2.5	1
32	Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. <i>Bone Marrow Transplantation</i> , 2021, 56, 9-19.	1.3	22
33	Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 683-685.	1.3	7
34	Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 55.e1-55.e7.	0.6	7
35	Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 58-66.	0.6	21
36	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2021, 137, 2634-2645.	0.6	111

#	ARTICLE	IF	CITATIONS
37	Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?. <i>Blood</i> , 2021, 137, 1416-1423.	0.6	49
38	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 6-20.	0.6	45
39	Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee. <i>Bone Marrow Transplantation</i> , 2021, 56, 786-797.	1.3	5
40	Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?. <i>Journal of Clinical Oncology</i> , 2021, 39, 487-498.	0.8	27
41	Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes—Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 483.e1-483.e6.	0.6	52
42	Breast Implant-associated Anaplastic Large Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e272-e276.	0.2	7
43	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	3.3	45
44	Bronchoalveolar lavage-based COVID-19 testing in patients with cancer. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 65-70.	0.6	19
45	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. <i>Leukemia</i> , 2021, 35, 2076-2085.	3.3	28
46	Enteropathy-Associated T cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 140-147.	1.2	17
47	First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3006-3006.	0.8	5
48	Effect of time to relapse on overall survival (OS) in mantle cell lymphoma (MCL) patients (pts) following frontline high-dose therapy and autologous hematopoietic cell transplantation (autoHCT).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7521-7521.	0.8	0
49	Duration of response to loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma by demographic and clinical characteristics: Subgroup analyses from LOTIS 2.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7546-7546.	0.8	2
50	Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS7574-TPS7574.	0.8	4
51	Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 790-800.	5.1	211
52	Cellular Therapies for Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 363-370.	0.6	6
53	Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e775-e781.	0.2	0
54	Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. <i>Lancet Haematology</i> , the, 2021, 8, e433-e445.	2.2	53

#	ARTICLE	IF	CITATIONS
55	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021, 107, 301-310.	1.1	3
56	Ruxolitinib resistance or intolerance in steroidâ€‘refractory acute graftâ€‘versus â€‘host disease â€‘ a realâ€‘world outcomes analysis. <i>British Journal of Haematology</i> , 2021, 195, 429-432.	1.2	6
57	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. <i>JAMA Oncology</i> , 2021, 7, 993.	3.4	44
58	Risk Factors for Cost-Related Delays to Medical Care Among Lymphoma Patients: A 22-Year Analysis of a Nationally Representative Sample. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e619-e625.	0.2	5
59	The impact of post-hematopoietic stem cell transplant tyrosine kinase inhibitors in Philadelphia-positive acute lymphoblastic leukemia. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.6	2
60	Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 2763-2770.	1.3	25
61	Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 911.e1-911.e7.	0.6	6
62	Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 885-907.	0.6	12
63	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 642-649.	0.6	65
64	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2911-2921.	1.3	21
65	Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. <i>Blood</i> , 2021, 138, 1278-1281.	0.6	101
66	Multiâ€‘center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2021, 96, 1374-1384.	2.0	11
67	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphomaâ€‘type Richter syndrome. <i>Blood Advances</i> , 2021, 5, 3528-3539.	2.5	24
68	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 720-728.	0.6	7
69	CAR T-cell therapy for secondary CNS DLBCL. <i>Blood Advances</i> , 2021, 5, 5626-5630.	2.5	41
70	ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S377-S378.	0.2	2
71	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021, 5, 5179-5189.	2.5	21
72	Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2021, 195, 757-763.	1.2	5

#	ARTICLE	IF	CITATIONS
73	Epidemiology of Food Insecurity in a Nationally Representative Sample of Lymphoma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	3
74	A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 19-24.	1.2	5
75	Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1313-1320.	1.1	2
76	The impact of beta-blocker use at the time of hematopoietic cell transplantation on the development of acute and chronic graft-versus-host disease. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.6	0
77	The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine Achieved Responses in Patients with Diffuse Large B-Cell Lymphoma Who Relapsed after Anti-CD19 CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 2489-2489.	0.6	1
78	Bispecific LV20.19 CAR T-Cells Expanded in IL-7 and IL-15 Have Greater Polyfunctionality and Polyfunctional Strength Than CAR T-Cells Expanded in IL-2. <i>Blood</i> , 2021, 138, 1728-1728.	0.6	0
79	Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial. <i>Blood</i> , 2021, 138, 3575-3575.	0.6	2
80	Lintuzumab-Ac225 in Combination with CLAG-M Yields High MRD (-) Responses in R/R AML with Adverse Features: Interim Results of a Phase I Study. <i>Blood</i> , 2021, 138, 3414-3414.	0.6	3
81	Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 247-253.	0.9	5
82	Did brentuximab vedotin™s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results?. <i>Haematologica</i> , 2021, , .	1.7	0
83	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 472-479.	2.0	21
84	Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e77-e85.	2.0	41
85	Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease. <i>Leukemia and Lymphoma</i> , 2020, 61, 869-874.	0.6	14
86	Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 1273-1283.	0.8	281
87	Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2229-2236.	2.0	4
88	Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. <i>Nature Medicine</i> , 2020, 26, 1569-1575.	15.2	266
89	<p>Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease</p>. <i>Journal of Experimental Pharmacology</i> , 2020, Volume 12, 549-557.	1.5	8
90	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	2.5	18

#	ARTICLE	IF	CITATIONS
91	Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2011-2017.	2.0	11
92	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2181-2189.	2.0	51
93	Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1876-1885.	2.0	4
94	CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. <i>Blood Advances</i> , 2020, 4, 3850-3852.	2.5	46
95	Allogeneic Transplant Conditioning Regimens for Patients With Non-Hodgkin Lymphoma—Reply. <i>JAMA Oncology</i> , 2020, 6, 1984.	3.4	1
96	Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression. <i>British Journal of Haematology</i> , 2020, 190, e98-e101.	1.2	9
97	Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e161-e166.	2.0	38
98	Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. <i>JAMA Oncology</i> , 2020, 6, 1011.	3.4	39
99	Trends in the use of therapeutic plasma exchange in multiple myeloma. <i>Journal of Clinical Apheresis</i> , 2020, 35, 307-315.	0.7	4
100	Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. <i>Cancer</i> , 2020, 126, 2791-2801.	2.0	6
101	Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1247-1256.	2.0	139
102	Myeloablative versus Reduced-Intensity Hematopoietic Cell Transplantation in Myelodysplastic Syndromes: Systematic Review and Meta-analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e138-e141.	2.0	8
103	Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1288-1297.	2.0	10
104	Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1670-1678.	2.0	17
105	Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. <i>Journal of Clinical Oncology</i> , 2020, 38, 1518-1526.	0.8	34
106	Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 893-901.	2.0	13
107	Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 190, 573-582.	1.2	19
108	Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1312-1317.	2.0	49

#	ARTICLE	IF	CITATIONS
109	Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. <i>Blood</i> , 2020, 135, 97-107.	0.6	56
110	Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 423-427.	1.9	8
111	Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. <i>Blood Advances</i> , 2020, 4, 47-54.	2.5	20
112	Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. <i>Blood Advances</i> , 2020, 4, 467-476.	2.5	39
113	Outcomes of rituximab+BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020, 126, 2279-2287.	2.0	17
114	Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1099-1105.	2.0	7
115	Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e177-e182.	2.0	378
116	Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 9-10.	0.6	4
117	Pharmacokinetic and Pharmacodynamic Correlates from the Phase 1 Study of Camidanlumab Tesirine (Cami) in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 35-36.	0.6	3
118	A Phase I Study of Lintuzumab Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML. <i>Blood</i> , 2020, 136, 9-10.	0.6	3
119	Superiority of Thiotepa-Containing Conditioning Regimens in Patients with Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS) Undergoing Autologous Hematopoietic Cell Transplantation (autoHCT). <i>Blood</i> , 2020, 136, 8-9.	0.6	12
120	Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 35-37.	0.6	14
121	A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen. <i>Blood</i> , 2020, 136, 44-45.	0.6	2
122	Is autologous transplantation (autoHCT) in relapsed diffuse large B-cell lymphoma (DLBCL) patients achieving only a PET/CT positive partial remission (PR) appropriate in the CAR-T cell era?. <i>Journal of Clinical Oncology</i> , 2020, 38, 8000-8000.	0.8	4
123	Allogeneic Transplant Outcomes for T-Cell Lymphomas: A Single Center Analysis. <i>Blood</i> , 2020, 136, 20-21.	0.6	0
124	Single-Cell Cytokine Analysis of LV20.19 Bispecific CAR T-Cell Products from a Phase I Clinical Trial. <i>Blood</i> , 2020, 136, 22-22.	0.6	2
125	Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. <i>Blood Advances</i> , 2019, 3, 1661-1669.	2.5	21
126	Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 210-215.	1.4	2

#	ARTICLE	IF	CITATIONS
127	A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e305-e309.	2.0	1
128	Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 56.	2.8	15
129	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	3.2	10
130	Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. <i>JAMA Network Open</i> , 2019, 2, e196476.	2.8	12
131	An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. <i>Journal of Clinical Apheresis</i> , 2019, 34, 686-691.	0.7	3
132	Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis. <i>Cancer</i> , 2019, 125, 4417-4425.	2.0	16
133	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2305-2321.	2.0	132
134	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. <i>Leukemia</i> , 2019, 33, 1736-1746.	3.3	45
135	Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1859-1868.	2.0	58
136	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2330-2337.	2.0	22
137	FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?. <i>Journal of Clinical Oncology</i> , 2019, 37, 1604-1607.	0.8	29
138	Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1456-1464.	2.0	18
139	Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1689-1694.	2.0	70
140	A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1492-1497.	2.0	23
141	Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation. <i>JAMA Oncology</i> , 2019, 5, 715.	3.4	44
142	Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. <i>Blood Advances</i> , 2019, 3, 2836-2844.	2.5	38
143	Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. <i>Blood Advances</i> , 2019, 3, 875-883.	2.5	25
144	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. <i>Blood Advances</i> , 2019, 3, 360-369.	2.5	92

#	ARTICLE	IF	CITATIONS
145	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	2.5	89
146	HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. <i>Blood Advances</i> , 2019, 3, 2581-2585.	2.5	27
147	A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 6986-6994.	3.2	77
148	Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database. <i>Oncologist</i> , 2019, 24, 1488-1495.	1.9	9
149	Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis. <i>Blood Cancer Journal</i> , 2019, 9, 97.	2.8	11
150	Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 95-102.	0.2	9
151	Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 827-833.	2.0	23
152	Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. <i>Bone Marrow Transplantation</i> , 2019, 54, 1094-1106.	1.3	36
153	Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. <i>Journal of Hematology and Oncology</i> , 2019, 12, 6.	6.9	29
154	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. <i>Leukemia and Lymphoma</i> , 2019, 60, 940-946.	0.6	3
155	Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e33-e38.	2.0	10
156	What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or R-DA-EPOCH? Response to Melani <i>et al</i> . <i>British Journal of Haematology</i> , 2019, 184, 838-840.	1.2	0
157	Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study. <i>Blood</i> , 2019, 134, 2605-2605.	0.6	5
158	BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD+ AML. <i>Blood</i> , 2019, 134, 4602-4602.	0.6	25
159	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort. <i>Blood</i> , 2019, 134, 775-775.	0.6	5
160	Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 4465-4465.	0.6	6
161	Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 757-757.	0.6	7
162	Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 753-753.	0.6	9

#	ARTICLE	IF	CITATIONS
163	Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 3997-3997.	0.6	1
164	Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 3483-3483.	0.6	1
165	Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant. <i>Blood</i> , 2019, 134, 1525-1525.	0.6	10
166	Population Level Outcomes of Chronic Lymphocytic Leukemia in the Era of Targeted Agents- Analysis of Surveillance Epidemiology and End Results (SEER) Database. <i>Blood</i> , 2019, 134, 1757-1757.	0.6	1
167	Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2510-2510.	0.8	35
168	60th ASH Annual Meeting Wrap-up: A Game Changer in San Diego. , 2019, 16, .		0
169	Does Addition of Rituximab (R) to BEAM Conditioning Improve Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)?. <i>Blood</i> , 2019, 134, 785-785.	0.6	0
170	The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 5891-5891.	0.6	0
171	Making Progress in Graft-Versus-Host Disease Prophylaxis and Microbiome Analysis in the Blood and Marrow Transplant Clinical Trials Network: Progress III (1703)/MI-Immune (1801). <i>Blood</i> , 2019, 134, 2005-2005.	0.6	0
172	A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404. <i>Blood</i> , 2019, 134, 1541-1541.	0.6	0
173	Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure. <i>Blood</i> , 2019, 134, 1554-1554.	0.6	0
174	Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. <i>Haematologica</i> , 2018, 103, 717-727.	1.7	38
175	Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. <i>Bone Marrow Transplantation</i> , 2018, 53, 1210-1213.	1.3	7
176	Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. <i>Cancer</i> , 2018, 124, 2306-2315.	2.0	40
177	Voxtalib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. <i>Lancet Haematology</i> , 2018, 5, e170-e180.	2.2	44
178	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <i>Cancer</i> , 2018, 124, 2541-2551.	2.0	61
179	Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. <i>Cancer</i> , 2018, 124, 1733-1742.	2.0	58
180	Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1379-1385.	2.0	19

#	ARTICLE	IF	CITATIONS
181	Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 983-988.	2.0	5
182	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 535-555.	1.3	75
183	Râ€œ<sc>CHOP </sc><i>versus</i> doseâ€œadjusted Râ€œ<sc>EPOCH</sc> in frontline management of primary mediastinal Bâ€œcell lymphoma: a multiâ€œcentre analysis. <i>British Journal of Haematology</i> , 2018, 180, 534-544.	1.2	70
184	Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction. <i>JAMA Oncology</i> , 2018, 4, 343.	3.4	130
185	Haploidentical Hematopoietic Cell Transplantation in Lymphomas. , 2018, , 245-260.		0
186	Peripheral Blood Grafts for T Cellâ€œReplete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1664-1670.	2.0	36
187	ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1119-1124.	2.0	33
188	Incidence and survival trends in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018, 181, 703-706.	1.2	46
189	Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 478-485.	2.0	31
190	Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 78-85.	2.0	9
191	Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 228-241.	2.0	43
192	Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 105-111.	0.6	7
193	Indications for Allogeneic Hematopoietic Stem Cell Transplantation in Adults. , 2018, , 83-109.		2
194	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1163-1171.	2.0	105
195	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 486-493.	2.0	3
196	Longâ€œterm outcomes among 2â€œyear survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large bâ€œcell lymphoma. <i>Cancer</i> , 2018, 124, 816-825.	2.0	44
197	Allogeneic haematopoietic cell transplantation for extranodal natural killer/Tâ€œcell lymphoma, nasal type: a <sc>CIBMTR</sc> analysis. <i>British Journal of Haematology</i> , 2018, 182, 916-920.	1.2	59
198	Choosing the appropriate salvage therapy for B-cell non-Hodgkin lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1631-1634.	0.9	3

#	ARTICLE	IF	CITATIONS
199	Advances in transplantation for lymphomas resulting from CIBMTR lymphoma working committee's research portfolio: A five-year report (2013-2018). <i>Advances in Cell and Gene Therapy</i> , 2018, 1, e17.	0.6	0
200	Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2018, 2, 299-307.	2.5	69
201	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018, 2, 933-940.	2.5	27
202	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. <i>Leukemia Research</i> , 2018, 74, 130-136.	0.4	47
203	Incidence and survival of therapy related myeloid neoplasm in United States. <i>Leukemia Research</i> , 2018, 71, 95-99.	0.4	24
204	Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. <i>BMC Cancer</i> , 2018, 18, 593.	1.1	28
205	Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1610-1614.	2.0	8
206	Reply to the persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular lymphoma. <i>Cancer</i> , 2018, 124, 3455-3456.	2.0	0
207	Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2862-2870.	0.6	13
208	A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 4193-4193.	0.6	27
209	T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes. <i>Blood</i> , 2018, 132, 1015-1015.	0.6	2
210	Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma. <i>Blood</i> , 2018, 132, 1658-1658.	0.6	16
211	Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 398-398.	0.6	8
212	Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study. <i>Blood</i> , 2018, 132, 2874-2874.	0.6	12
213	Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 928-928.	0.6	36
214	Post-transplant cyclophosphamide (PT-Cy) based haploidentical transplantation (haploHCT) versus matched sibling (MSD) or matched unrelated donor (MUD) reduced intensity conditioning (RIC) HCT for diffuse large b-cell lymphoma (DLBCL): A CIBMTR and EBMT analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7056-7056.	0.8	2
215	A phase 3, trial of gilteritinib, as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7075-TPS7075.	0.8	17
216	Intensive Induction Regimens after Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2018, 132, 4153-4153.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Improvements in Clinical Outcomes of Advanced Stage Classical Hodgkin Lymphoma in the United States from 2000-2014: Analysis of Surveillance Epidemiology and End Results Database. <i>Blood</i> , 2018, 132, 2939-2939.	0.6	0
218	Incidence and Predictors of 30-Day Readmissions Following Autologous Hematopoietic Cell Transplantation (auto-HCT) in the US. <i>Blood</i> , 2018, 132, 3544-3544.	0.6	0
219	Trends in Post-Relapse Survival in Classical Hodgkin Lymphoma Patients after Experiencing Therapy Failure Following Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 2918-2918.	0.6	0
220	Association between Transplant Volumes and 30-Day Readmissions Following Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in the US. <i>Blood</i> , 2018, 132, 617-617.	0.6	0
221	Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2018, 132, 1998-1998.	0.6	0
222	Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) on the Outcomes of Angioimmunoblastic T-Cell Lymphoma (AITL): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. <i>Blood</i> , 2018, 132, 969-969.	0.6	0
223	Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 165-172.	0.2	17
224	Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma: a real world study. <i>Hematological Oncology</i> , 2017, 35, 528-535.	0.8	56
225	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 767-775.	2.0	41
226	Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2017, 35, 1154-1161.	0.8	495
227	Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 853-856.	2.0	28
228	Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment?. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 47-56.	0.6	7
229	Treatment of severe mucositis pain with oral ketamine mouthwash. <i>Supportive Care in Cancer</i> , 2017, 25, 2215-2219.	1.0	23
230	Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 408-414.	0.2	8
231	PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. <i>Blood</i> , 2017, 130, 221-228.	0.6	214
232	Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1295-1302.	2.0	8
233	Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 277-284.	0.6	27
234	Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 117.	6.9	20

#	ARTICLE	IF	CITATIONS
235	Systemic Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 201-206.	0.2	9
236	Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 305-311.e2.	0.2	6
237	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <i>British Journal of Haematology</i> , 2017, 179, 781-789.	1.2	56
238	Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. <i>Contemporary Clinical Trials Communications</i> , 2017, 8, 33-38.	0.5	17
239	MYC+ relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional hits and outcomes with subsequent therapy. <i>Cancer</i> , 2017, 123, 4411-4418.	2.0	23
240	Alpha-1 antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. <i>American Journal of Hematology</i> , 2017, 92, E610-E611.	2.0	7
241	Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. <i>Haematologica</i> , 2017, 102, 1767-1775.	1.7	48
242	Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1955-1960.	2.0	24
243	Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1826-1838.	2.0	135
244	Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. <i>American Journal of Hematology</i> , 2017, 92, E563-E565.	2.0	4
245	Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 60-66.	2.0	17
246	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 269-277.	2.0	19
247	Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. <i>American Journal of Hematology</i> , 2017, 92, 161-170.	2.0	56
248	Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?. <i>Journal of Oncology Practice</i> , 2017, 13, 798-806.	2.5	13
249	Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2017, 35, 3002-3009.	0.8	255
250	Autologous (auto) versus matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic (allo) hematopoietic cell transplantation (HCT) in follicular lymphoma (FL) patients (pts) with early chemoimmunotherapy failure (ECF): A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 7508-7508.	0.8	1
251	MYC+ relapsed and refractory (R/R) diffuse large b-cell lymphoma (DLBCL): Impact of additional hits and outcomes with subsequent therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 7541-7541.	0.8	0
252	Allogeneic hematopoietic cell transplantation for myelofibrosis (MF) in high risk patients. <i>Journal of Clinical Oncology</i> , 2017, 35, 7062-7062.	0.8	0

#	ARTICLE	IF	CITATIONS
253	Bendamustine with ixazomib and dexamethasone (BID) for double refractory relapsed multiple myeloma (RRMM): Phase I safety and dosing results.. Journal of Clinical Oncology, 2017, 35, 8012-8012.	0.8	0
254	Allogeneic stem cell transplant (AHCT) in the eighth decade: Age is just a number.. Journal of Clinical Oncology, 2017, 35, 7045-7045.	0.8	0
255	Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review. Future Oncology, 2016, 12, 2631-2642.	1.1	17
256	Pediatricâ€inspired therapy compared to allografting for <scp>P</scp>hiladelphia chromosomeâ€negative adult ALL in first complete remission. American Journal of Hematology, 2016, 91, 322-329.	2.0	72
257	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer, 2016, 122, 3005-3014.	2.0	45
258	Allogeneic transplantation provides durable remission in a subset of <scp>DLBCL</scp> patients relapsing after autologous transplantation. British Journal of Haematology, 2016, 174, 235-248.	1.2	115
259	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis. Biology of Blood and Marrow Transplantation, 2016, 22, 802-814.	2.0	37
260	Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 379-386.	0.2	17
261	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. Biology of Blood and Marrow Transplantation, 2016, 22, 1056-1064.	2.0	26
262	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. Biology of Blood and Marrow Transplantation, 2016, 22, 1493-1503.	2.0	55
263	Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. Biology of Blood and Marrow Transplantation, 2016, 22, 1543-1551.	2.0	42
264	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood, 2016, 127, 938-947.	0.6	246
265	Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 672-678.	0.2	7
266	Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. Best Practice and Research in Clinical Haematology, 2016, 29, 54-66.	0.7	7
267	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 2117-2125.	2.0	87
268	Think outside the box : Acanthamoeba encephalitis following autologous haematopoietic stem cell transplantation. British Journal of Haematology, 2016, 175, 758-758.	1.2	6
269	Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2016, 22, 1773-1780.	2.0	7
270	Impact of intravenous magnesium infusion rate during ambulatory replacements on serum magnesium concentrations after allogeneic stem cell transplant. Supportive Care in Cancer, 2016, 24, 4237-4240.	1.0	5

#	ARTICLE	IF	CITATIONS
271	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 3141-3149.	0.8	212
272	Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. <i>Immunotherapy</i> , 2016, 8, 435-447.	1.0	28
273	Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 666-678.	0.5	6
274	Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study. <i>Blood</i> , 2016, 128, 1786-1786.	0.6	6
275	Autologous Hematopoietic Cell Transplantation in Patients with Multiple Myeloma: IMPACT of Age. <i>Blood</i> , 2016, 128, 3456-3456.	0.6	1
276	Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. <i>Blood</i> , 2016, 128, 683-683.	0.6	3
277	Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1. <i>Journal of Clinical Oncology</i> , 2016, 34, 8039-8039.	0.8	2
278	Phase I Study of Combination Chemotherapy Plus Ixazomib in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma (ALL). <i>Blood</i> , 2016, 128, 5192-5192.	0.6	0
279	Primary Failure Diffuse Large B Cell Lymphoma: Early Autologous or Donor Hematopoietic Cell Transplantation Not Effective in Patients with Ultra-High Risk Features. <i>Blood</i> , 2016, 128, 513-513.	0.6	0
280	Reduced-Intensity or Myeloablative Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: A Side-By-Side Systematic Review/Meta-Analysis. <i>Blood</i> , 2016, 128, 3551-3551.	0.6	0
281	Impact of Obesity on Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Myeloid Malignancies. <i>Blood</i> , 2016, 128, 4667-4667.	0.6	0
282	Carfilzomib Plus High Dose Melphalan Conditioning Prior to Autologous Hematopoietic Cell Transplantation Followed by Carfilzomib Maintenance in Patients with Relapsed Multiple Myeloma. <i>Blood</i> , 2016, 128, 4630-4630.	0.6	0
283	Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Identification of Ultra-High Risk Patients and Benchmarking for Experimental Therapies. <i>Blood</i> , 2016, 128, 103-103.	0.6	0
284	Impact of Pretransplantation 18F-fluorodeoxy Glucose Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1605-1611.	2.0	39
285	A Phase I Study of Midostaurin and Azacitidine in Relapsed and Elderly AML Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 428-432.e2.	0.2	68
286	Randomized Controlled Trials in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 199-207.	0.2	1
287	Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 552-558.	2.0	12
288	Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1155-1166.	2.0	104

#	ARTICLE	IF	CITATIONS
289	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2091-2099.	2.0	55
290	Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4424-4428.	1.4	60
291	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1746-1753.	2.0	48
292	Ibrutinib in Refractory Classic Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2015, 373, 1381-1382.	13.9	35
293	Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use. <i>Cytotherapy</i> , 2015, 17, 1785-1792.	0.3	30
294	Survival after T-Cell Replete Haploidentical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor (MUD) Transplant for Lymphoid Malignancies. <i>Blood</i> , 2015, 126, 194-194.	0.6	1
295	Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901. <i>Blood</i> , 2015, 126, 1BA-8-1BA-8.	0.6	59
296	Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. <i>World Journal of Transplantation</i> , 2015, 5, 81.	0.6	3
297	A statistical model for predicting neutropenic fever.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18050-e18050.	0.8	0
298	Incidence of catheter-related venous thromboembolism in peripherally inserted central venous catheters vs tunneled chest central venous catheters in patients with hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20684-e20684.	0.8	0
299	Chemomobilization with (R)-ICE (rituximab, ifosfamide, carboplatin, etoposide) compared to G-CSF and plerixafor (G+P) mobilization in lymphoid malignancies.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7033-7033.	0.8	0
300	Association of reduced intensity conditioning (RIC) allograft (alloHCT) as first transplant approach in relapsed/refractory grade 3(G-3) follicular lymphoma (FL) with improved outcomes in long-term survivors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7009-7009.	0.8	0
301	Day 100 Absolute Lymphocyte Count (ALC) Predicts Risk of Serious Infections in Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2015, 126, 3168-3168.	0.6	0
302	Myeloablative or Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Mantle Cell Lymphoma? a Systematic Review and Meta-Analysis. <i>Blood</i> , 2015, 126, 2097-2097.	0.6	0
303	Impact of Immunophenotype and Cytogenetics in Early Assessment of Post Induction Response in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 4954-4954.	0.6	0
304	Impact of Routine Surveillance Imaging on Outcomes in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT). <i>Blood</i> , 2015, 126, 4360-4360.	0.6	0
305	Allogeneic Stem Cell Transplantation for Relapsed / Refractory (R/R) Follicular Lymphoma (FL). a Joint Study Between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). <i>Blood</i> , 2015, 126, 198-198.	0.6	0
306	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T-Cell Lymphomas As Front-Line Consolidation or in the Relapsed/Refractory Setting: A Meta-Analysis. <i>Blood</i> , 2015, 126, 4493-4493.	0.6	0

#	ARTICLE	IF	CITATIONS
307	Impact of Routine Surveillance Imaging on Outcomes in Patients with Classical Hodgkin Lymphoma (cHL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT). <i>Blood</i> , 2015, 126, 3169-3169.	0.6	0
308	Local Control of Ocular Adnexal Lympho-Proliferative Disorders (OALD): Similar Outcomes in MALT and Non-MALT Histologies. <i>Blood</i> , 2015, 126, 2711-2711.	0.6	0
309	Reply to S. Fuji et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 1860-1861.	0.8	0
310	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1503-1512.	5.1	233
311	Predictors and Impact of Thirty-Day Readmission on Patient Outcomes and Health Care Costs after Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 415-420.	2.0	16
312	Management of Relapses After Hematopoietic Cell Transplantation in T-Cell Non-Hodgkin Lymphomas. <i>Seminars in Hematology</i> , 2014, 51, 73-86.	1.8	10
313	Plerixafor and Abbreviated-Course Granulocyte Colony-Stimulating Factor for Mobilizing Hematopoietic Progenitor Cells in Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1926-1931.	2.0	23
314	Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation Timing and Modality. <i>Journal of Clinical Oncology</i> , 2014, 32, 273-281.	0.8	133
315	Autologous hematopoietic cell transplantation: An update for clinicians. <i>Annals of Medicine</i> , 2014, 46, 619-632.	1.5	14
316	Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1729-1736.	2.0	119
317	Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 89-97.	2.0	130
318	Limited Utility of Surveillance Imaging for Detecting Disease Relapse in Patients With Non-Hodgkin Lymphoma in First Complete Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 50-55.	0.2	28
319	Allotransplantation for Patients Age ≥ 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.	2.0	37
320	Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 951-959.	2.0	37
321	Antithymocyte Globulin in Reduced-Intensity Conditioning Allografting: Is the Benefit Simply in the Eyes of the Transplanter?. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 292-294.	2.0	2
322	Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. <i>World Journal of Stem Cells</i> , 2014, 6, 69.	1.3	29
323	Cost and Efficacy of Upfront Plerixafor Versus a "Just-in-Time" (JIT) Approach in Hematopoietic Progenitor Cell (HPC) Mobilization. <i>Blood</i> , 2014, 124, 1127-1127.	0.6	10
324	Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results. <i>Blood</i> , 2014, 124, 82-82.	0.6	18

#	ARTICLE	IF	CITATIONS
325	Early rituximab failure (ERF) in relapsed diffuse large b-cell lymphoma (DLBCL) and prediction of futility of autologous hematopoietic cell transplantation (AHCT).. Journal of Clinical Oncology, 2014, 32, 7048-7048.	0.8	0
326	A Statistical Model for Predicting Neutropenic Fever. Blood, 2014, 124, 5258-5258.	0.6	0
327	Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapyâ€era with plerixafor and Gâ€CSF has superior efficacy but significantly higher costs compared to mobilization with lowâ€dose cyclophosphamide and Gâ€CSF. Journal of Clinical Apheresis, 2013, 28, 359-367.	0.7	25
328	Impact of Pretransplantation Conditioning Regimens onâ€Outcomes of Allogeneic Transplantation for Chemotherapy-Unresponsive Diffuse Large B Cell Lymphoma and Grade III Follicular Lymphoma. Biology of Blood and Marrow Transplantation, 2013, 19, 746-753.	2.0	83
329	Sibling Donor and Recipient Immune Modulation With Atorvastatin for the Prophylaxis of Acute Graft-Versus-Host Disease. Journal of Clinical Oncology, 2013, 31, 4416-4423.	0.8	33
330	Diagnostic and Therapeutic Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm: A Focus onâ€Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1006-1012.	2.0	75
331	Rituximab maintenance versus retreatment in follicular lymphoma. Hematological Oncology, 2013, 31, 171-178.	0.8	5
332	Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2013, 19, 173-179.	2.0	38
333	Monoclonal Antibodies in Conditioning Regimens forâ€Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1288-1300.	2.0	11
334	Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2013, 19, 625-631.	2.0	91
335	Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Journal of Hematology and Oncology, 2013, 6, 2.	6.9	42
336	Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin. Bone Marrow Research, 2013, 2013, 1-8.	1.7	10
337	Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and metaâ€analysis. British Journal of Haematology, 2013, 163, 315-325.	1.2	35
338	Predictors and Impact Of 30-Day Readmissions On Patient Outcomes and Healthcare Costs After Allogeneic Hematopoietic Cell Transplantation. Blood, 2013, 122, 1718-1718.	0.6	0
339	Controversies and Recent Advances in Hematopoietic Cell Transplantation for Follicular Non-Hodgkin Lymphoma. Bone Marrow Research, 2012, 2012, 1-11.	1.7	2
340	Intermediate-Dose versus Low-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Therapies. Biology of Blood and Marrow Transplantation, 2012, 18, 1128-1135.	2.0	59
341	Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis. International Journal of Antimicrobial Agents, 2012, 40, 557-561.	1.1	14
342	Impact of alcohol-impregnated port protectors and needleless neutral pressure connectors on central lineâ€associated bloodstream infections and contamination of blood cultures in an inpatient oncology unit. American Journal of Infection Control, 2012, 40, 931-934.	1.1	70

#	ARTICLE	IF	CITATIONS
343	Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1446-1454.	2.0	22
344	Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization. <i>Journal of Oncology</i> , 2012, 2012, 1-5.	0.6	9
345	Regulation of acute graft-versus-host disease by microRNA-155. <i>Blood</i> , 2012, 119, 4786-4797.	0.6	128
346	A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM). <i>Blood</i> , 2012, 120, 332-332.	0.6	12
347	Effect of Graft Source and Transplant Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Mantle Cell Lymphoma (MCL): A CIBMTR Analysis. <i>Blood</i> , 2012, 120, 815-815.	0.6	1
348	CD103 Deficiency Prevents Graft-versus-Host Disease but Spares Graft-versus-Tumor Effects Mediated by Alloreactive CD8 T Cells. <i>PLoS ONE</i> , 2011, 6, e21968.	1.1	14
349	Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. <i>Blood</i> , 2011, 118, 1979-1988.	0.6	77
350	Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Myeloid Leukemia. <i>Cancer Control</i> , 2011, 18, 237-245.	0.7	33
351	Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2011, 4, 149-156.	0.6	9
352	Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. <i>Hematological Oncology</i> , 2011, 29, 202-210.	0.8	14
353	The evolving role of statins in hematopoietic stem and progenitor cell transplantation. <i>American Journal of Blood Research</i> , 2011, 1, 57-64.	0.6	2
354	Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia. <i>Hematological Oncology</i> , 2010, 28, 3-12.	0.8	9
355	Malignant Thymoma With Immunodeficiency (Good Syndrome) Associated With Mucormycosis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 109.	0.6	4
356	Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2010, 148, 623-626.	1.2	4
357	Mantle Cell Lymphoma 12 Years After Allogeneic Bone Marrow Transplantation Occurring Simultaneously in Recipient and Donor. <i>Journal of Clinical Oncology</i> , 2010, 28, e629-e632.	0.8	31
358	Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2010, 51, 243-251.	0.6	15
359	How we approach patient evaluation for hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2010, 45, 1259-1268.	1.3	71
360	Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 349-356.	0.6	12

#	ARTICLE	IF	CITATIONS
361	Allogeneic Stem Cell Transplantation for Patients with Relapsed Chemorefractory Aggressive Non-Hodgkin Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 547-553.	2.0	39
362	Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1422-1430.	2.0	89
363	The Role of Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia. <i>Clinical Leukemia</i> , 2009, 3, 47-57.	0.2	0
364	Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1232-1234.	0.6	0
365	Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can. <i>Blood</i> , 2009, 114, 2564-2566.	0.6	22
366	High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2008, 81, 425-431.	1.1	35
367	The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 351-352.	2.0	8
368	Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T Cell Lymphomas; Evidence of Graft-Versus-T Cell Lymphoma Effect. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 480-483.	2.0	38
369	Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 556-567.	2.0	34
370	Addition of Infliximab to Standard Acute Graft-versus-Host Disease Prophylaxis following Allogeneic Peripheral Blood Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 783-789.	2.0	68
371	Can Rituximab Change the Usually Dismal Prognosis of Patients With Intravascular Large B-Cell Lymphoma?. <i>Journal of Clinical Oncology</i> , 2008, 26, 5134-5136.	0.8	61
372	Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1893-1898.	0.6	10
373	The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. <i>Blood</i> , 2008, 111, 3901-3902.	0.6	42
374	Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 3300-3300.	0.6	0
375	A Cumulative Series from 14 Western Countries Suggests That Rituximab Significantly Changed the Dismal Natural History of Intravascular Large B-Cell Lymphoma (IVL) .. <i>Blood</i> , 2008, 112, 2008-2008.	0.6	0
376	Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2008, 112, 2170-2170.	0.6	0
377	Assessment of Rabbit Antithymocyte Globulin (rATG) Dose-Intensity in Patients with Hematological Malignancies Undergoing Allogeneic Stem Cell Transplantation (ASCT) Following Reduced Intensity Conditioning (RIC) with Fludarabine, Busulfan and rATG (FBA). <i>Blood</i> , 2008, 112, 4405-4405.	0.6	0
378	Allogeneic Stem Cell Transplantation for Patients with Chemo-Refractory or Progressive Aggressive Non-Hodgkin's Lymphomas.. <i>Blood</i> , 2008, 112, 3265-3265.	0.6	0

#	ARTICLE	IF	CITATIONS
379	Review: isolated skeletal involvement in hairy cell leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 294-6.	0.3	1
380	Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?. <i>Journal of Oncology Pharmacy Practice</i> , 2007, 13, 69-75.	0.5	22
381	Gastrointestinal chronic graft-versus-host disease: management options. <i>Journal of Oncology Pharmacy Practice</i> , 2007, 13, 49-51.	0.5	2
382	Gastroparesis. <i>Southern Medical Journal</i> , 2007, 100, 281-286.	0.3	22
383	False-Negative PET Scan With Bronchioloalveolar Carcinoma: An Important Diagnostic Caveat. <i>American Journal of the Medical Sciences</i> , 2007, 334, 311-313.	0.4	8
384	Dramatic response to single-agent rituximab in a patient with intravascular lymphoma. <i>American Journal of Hematology</i> , 2007, 82, 1120-1121.	2.0	2
385	CD4+CD56+haematodermic tumour (plasmacytoid dendritic cell neoplasm). <i>British Journal of Haematology</i> , 2007, 140, 071107173701001-???	1.2	2
386	Paraneoplastic Sweet's syndrome and the pathergy phenomenon. <i>Annals of Hematology</i> , 2007, 86, 613-614.	0.8	14
387	The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Patients with Multiple Myeloma. <i>Blood</i> , 2007, 110, 5129-5129.	0.6	0
388	Increased Mean Corpuscular Volume after Autologous Hematopoietic Stem Cell Transplantation: Incidence and Significance. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 111-112.	2.0	5
389	Role of intra-arterial steroid administration in the management of steroid-refractory acute gastrointestinal graft-versus-host disease. <i>American Journal of Hematology</i> , 2006, 81, 959-962.	2.0	18
390	Role of thiamine in managing ifosfamide-induced encephalopathy. <i>Journal of Oncology Pharmacy Practice</i> , 2006, 12, 237-239.	0.5	42
391	Delayed myeloid engraftment due to vancomycin in allogeneic haematopoietic stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 795-796.	1.3	5
392	Early Detection of Digitalis-induced Nonocclusive Mesenteric Ischemia Using Doppler Ultrasonography. <i>Southern Medical Journal</i> , 2006, 99, 1142.	0.3	2
393	Marginal zone B-cell lymphoma of the uterus: a case report and review of the literature. <i>Journal - Oklahoma State Medical Association</i> , 2006, 99, 154-6.	0.4	8
394	Fibrous dysplasia protuberans in a patient with McCune-Albright syndrome. <i>Journal of the College of Physicians and Surgeons--Pakistan: JCPSP</i> , 2006, 16, 376-7.	0.2	6
395	Granulocytic Sarcoma Manifesting as Multiple Skeletal Lesions. <i>American Journal of the Medical Sciences</i> , 2005, 330, 139-143.	0.4	10